Case Reports in Medicine

Case Reports in Medicine / 2012 / Article

Case Report | Open Access

Volume 2012 |Article ID 980920 |

Andrew Meyer, Rachel Angelica Mariani, Chadi Nabhan, "Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma", Case Reports in Medicine, vol. 2012, Article ID 980920, 3 pages, 2012.

Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma

Academic Editor: Jahn M. Nesland
Received13 Jun 2012
Accepted02 Jul 2012
Published08 Aug 2012


A 63-year-old man with castrate-resistant metastatic prostate adenocarcinoma with known osseous and pelvic nodal involvement presented with progressive dyspnea for one week. Complete cardiopulmonary evaluation revealed a restrictive lung defect that could not be attributed to any of his previous therapies. On presentation, physical examination revealed coarse breath sounds diffusely with hypoxemia. Computed tomography of the chest showed severe bilateral airspace opacities and ground-glass appearance most consistent with interstitial pneumonitis. The patient was intubated due to progressive hypoxemia and worsening respiratory status despite empiric antibiotics and high dose steroids. Subsequent emergent bronchoscopy with transbronchial biopsies revealed atypical intralymphatic cells that stained positively for prostate-specific antigen and prostatic-specific acid phosphatase, confirming the diagnosis of intralymphatic pulmonary metastasis from prostate adenocarcinoma. Lymphangitic pulmonary metastasis from prostate adenocarcinoma is exceedingly rare, with few reported cases that are biopsy-proven. Herein, we describe a rare case of biopsy-proven lymphangitic pulmonary metastasis in the setting of castrate-resistant prostate adenocarcinoma and provide a comprehensive literature review.

1. Case

A 63-year-old man who has metastatic prostate cancer with known osseous and pelvic nodal involvement presented with a one-week history of progressive dyspnea. The patient had presented originally with metastatic disease 5 years prior to admission. He was treated with complete androgen deprivation therapy (ADT) attaining biochemical complete response that lasted for 2 years. Subsequently, he received sipuleucel-T on a clinical trial demonstrating stable disease radiographically for 18 months. Radiographic and biochemical progression necessitated treatment with lenalidomide on a phase II clinical trial. In total, he received 4.5 months of lenalidomide achieving partial biochemical response and stable disease radiographically. However, lenalidomide was discontinued 3 months prior to presentation due to shortness of breath and fatigue attributed initially to the study drug. Pulmonary function testing at that time showed a restrictive pattern and cardiac evaluation was nonrevealing. Dyspnea improved slightly after stopping lenalidomide and further improved with pulse steroids. He subsequently received temsirolimus for 3 weeks before hospitalization with the above-mentioned complaints.

On presentation, physical examination revealed coarse breath sounds bilaterally with hypoxemia. Computed tomography (CT) of the chest showed severe bilateral airspace opacities and ground-glass appearance most consistent with interstitial pneumonitis (Figure 1).

Empiric broad-spectrum antimicrobials and high-dose steroids were initiated but his respiratory status and hypoxemia worsened further. Emergent bronchoscopy revealed normal tracheobronchial trees bilaterally without evidence of inflammation or edema. Transbronchial biopsies revealed atypical intralymphatic cells with abundant cytoplasm and large nuclei with prominent nucleoli (Figure 2).

Subsequent immunostains for prostate-specific antigen (PSA) and prostatic-specific acid phosphatase (PSAP) confirmed intralymphatic involvement by prostate adenocarcinoma (Figures 3(a) and 3(b)). While systemic chemotherapy was offered in an attempt to improve his respiratory condition, the family opted for palliative measures, and the patient died 24 hours after extubation.

2. Discussion

Pulmonary lymphangitic carcinomatosis is pathologically described as the presence of tumor thrombi in the lymphatic vessels of bronchovascular bundles, interlobular septa, and pleura [1]. Clinically, the disease process can manifest as progressive dyspnea with subacute cor pulmonale and portends a poor prognosis. Imaging studies characteristically show multiple linear densities forming a reticular network with thickened and irregular bronchovascular bundles. Another common radiographic presentation of pulmonary lymphangitic carcinomatosis is the “tree-in-bud” pattern, which describes bronchiolar luminal impaction that outlines the normally invisible peripheral airway branching. Diagnosis is usually made based on clinical grounds but can be definitively established by obtaining a transbronchial lung biopsy.

In prostate cancer, lymphangitic pulmonary involvement is exceptionally rare, occurring in less than 0.2% of patients [9]. Nodular involvement, however, is more commonly observed. A retrospective review of preoperative chest X-rays for 91 patients with advanced prostate cancer undergoing bilateral orchiectomy revealed 3 patients with bilateral coarse infiltrates consistent with lymphangitic spread [10]. Several cases of presumed pulmonary lymphangitic spread from prostate cancer without confirmatory lung biopsy were identified [5, 11, 12]. Pulmonary lymphangitic spread of prostate cancer that is confirmed pathologically via lung biopsy is rarely reported. To our knowledge, only 7 cases described biopsy-proven lymphangitic metastasis from prostate cancer, but surprisingly none occurred in the castration-resistant setting (Table 1) [28]. We describe a rare case of biopsy-proven pulmonary lymphangitic metastasis in the castration-resistant setting.

ReferenceStatus of PC at time of lymphangitic spreadInitial pulmonary presentationLung biopsyOutcome

Miseria et al. [2]Hormone sensitiveDiffuse interstitial infiltrate with reticulonodular patternDoneClearing of infiltrates with ADT
Rossi et al. [3]Hormone sensitiveBilateral multiple small nodulesDoneGiven ADT, outcome not reported
K. S. Miller and J. M. Miller [4]Hormone sensitiveDiffuse, bilateral, reticulonodular infiltrateDoneNot reported
Cohen et al. [5]Hormone sensitiveBilateral interstitial infiltratesDoneReceived ADT followed by chemotherapy with radiographic improvement
Heffner et al. [6]After failing first-line hormonal therapy with DESLarge bilateral effusions with interstitial infiltrateDoneSecond-line hormonal therapy given
Arriero et al. [7]Hormone sensitiveBilateral interstitial densities with perihilar predominanceDoneImprovement with ADT but suffered SCD of unknown cause 4 months later
Schwarz et al. [8]Developed after failing first-line therapyDiffuse infiltrations and nodularityDoneImprovement after orchiectomy

ADT: androgen deprivation therapy, DES: diethylstilbestrol, SCD: sudden cardiac death.


  1. P. L. Munk, N. L. Muller, R. R. Miller, and D. N. Ostrow, “Pulmonary lymphangitic carcinomatosis: CT and pathologic findings,” Radiology, vol. 166, no. 3, pp. 705–709, 1988. View at: Google Scholar
  2. S. Miseria, U. Torresi, E. T. Menichetti et al., “Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report,” Tumori, vol. 77, no. 1, pp. 86–89, 1991. View at: Google Scholar
  3. G. Rossi, A. Cadioli, and C. Casali, “Double synchronous pulmonary lymphatic-related lesions,” International Journal of Surgical Pathology, vol. 16, no. 4, pp. 430–432, 2008. View at: Publisher Site | Google Scholar
  4. K. S. Miller and J. M. Miller, “Imaging case of the month. Pulmonary lymphangitic carcinomatosis from adenocarcinoma of the prostate,” Maryland Medical Journal, vol. 43, no. 11, pp. 989–990, 1994. View at: Google Scholar
  5. O. Cohen, L. Leibovici, and A. I. Wysenbeek, “Carcinoma of the prostate presenting as interstitial lung disease,” Respiration, vol. 51, no. 2, pp. 158–160, 1987. View at: Google Scholar
  6. J. E. Heffner, D. J. Duffey, and M. I. Schwarz, “Massive pleural effusions from prostatic lymphangitic carcinomatosis: resolution with endocrine therapy,” Archives of Internal Medicine, vol. 142, no. 2, pp. 375–376, 1982. View at: Publisher Site | Google Scholar
  7. J. M. Arriero, J. Gil, S. Romero, M. Masia, and J. A. Carratala, “Lung metastases from prostatic carcinoma: orchidectomy-induced remission in two patients,” Monaldi Archives for Chest Disease, vol. 49, no. 2, pp. 115–117, 1994. View at: Google Scholar
  8. M. I. Schwarz, L. C. Waddell, D. H. Dombeck, H. Weill, and M. M. Ziskind, “Prolonged survival in lymphangitic carcinomatosis,” Annals of Internal Medicine, vol. 71, no. 4, pp. 779–783, 1969. View at: Google Scholar
  9. M. M. Lindell, L. C. Doubleday, A. C. von Eschenbach, and H. I. Libshitz, “Mediastinal metastases from prostatic carcinoma,” Journal of Urology, vol. 128, no. 2, pp. 331–334, 1982. View at: Google Scholar
  10. M. E. Morin, G. A. MacNealy, A. Tan et al., “Hormonal manipulation of pulmonary metastases from carcinoma of the prostate,” Urologic Radiology, vol. 4, no. 1, pp. 23–27, 1982. View at: Google Scholar
  11. L. G. Lome and T. John, “Pulmonary manifestations of prostatic carcinoma,” Journal of Urology, vol. 109, no. 4, pp. 680–685, 1973. View at: Google Scholar
  12. J. W. Wu and C. Chiles, “Lymphangitic carcinomatosis from prostate carcinoma,” Journal of Computer Assisted Tomography, vol. 23, no. 5, pp. 761–763, 1999. View at: Publisher Site | Google Scholar

Copyright © 2012 Andrew Meyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.